Breaking News

Lupin to Acquire GAVIS for $880M

Will expand U.S. generics business and gain U.S. manufacturing site

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pharma Major Lupin Ltd. has entered a definitive agreement to acquire GAVIS Pharmaceuticals LLC and Novel Laboratories Inc., in a transaction valued at $880 million. The acquisition expands Lupin’s scale in the U.S. generic market and its pipeline in dermatology, controlled substance products and other high-value and niche generics. GAVIS brings a U.S.-based R&D organization that complements Lupin’s Coral Springs, FL, inhalation R&D center. GAVIS’s manufacturing facilit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters